Skip to content

Clinical Research on REBACIN Regression Cervicall High-grade Squamouse Intraepithelial Lesions

Clinical Research on REBACIN Regression Cervicall High-grade Squamouse Intraepithelial Lesions

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015617
Enrollment
Unknown
Registered
2018-04-11
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerical high grade squamous intraepithelial lesions

Interventions

Case series:REBACIN

Sponsors

Tianjin First Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. TCT imply LSIL or HSIL; 2. HPV positive or negative; 3. colposcopy: adequate, 1-2 transformation zone, lesions completely outside the cervix; 4. cervical biopsy pathology: CIN2-CIN3, ECC no abnormalities; 5. Patients desire fertility and strongly claim conservative treatment; 6. Patient had no fertility requirements but refused to undergo conization; 7. Patient had complete and full informed consent and fully understood the risks and benefits of the treatment; 8. Married patients must have informed consent of their husbands, and the unmarried patients must have informed consent of their father or mother or other authorized persons.

Exclusion criteria

Exclusion criteria: 1. TCT results is cancerous, abnormal glandular cells; 2. Incomplete colposcopy, type 3 transformation zone, part or all of the lesion within the cervical canal; 3. Cervical biopsy pathology: CIN2-CIN3, but ECC suggestive of high-grade cervical lesions; 4. The patient is pregnant, or suffor with immune disease, after organ transplantation, or other organ malignancy, combined with uterine and/or accessory lesions; 5. patients can not follow-up.

Design outcomes

Primary

MeasureTime frame
cervical biopsy pathology;

Secondary

MeasureTime frame
HPV;TCT;

Countries

China

Contacts

Public ContactQuanxin Qu

Tianjin First Central Hospital

xiaohuamaoyanshu@163.com+86 13820576123

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026